Improving topical microbicide applicators for use in resource-poor settings.

Program for Appropriate Technology in Health, Seattle, WA 98107, USA.
American Journal of Public Health (Impact Factor: 4.23). 08/2004; 94(7):1089-92. DOI: 10.2105/AJPH.94.7.1089
Source: PubMed

ABSTRACT With more than 60 potential microbicides being assessed in preclinical or clinical trials, most attention has been centered on products intended for topical application, with much less research conducted on the applicators that will be used to deliver the microbicides. However, applicator design relates to safety, efficacy, and acceptability. As the foundation for a more systematic approach to evaluating and possibly improving designs for topical microbicide applicators, we conducted a literature review and a series of interviews with microbicide developers, trial investigators, and trial sponsors. Our findings indicate that issues concerning applicator safety, reuse, and cost warrant further investigation.

Download full-text


Available from: Janet G Vail, Feb 10, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper reviews key issues found to affect acceptability and preferences for vaginal products to prevent HIV infection or HIV and pregnancy. We focus on the interplay between the biological and physico-chemical aspects of formulation and the social and behavioral issues that may affect use. The need for an HIV prevention product that women can use is driven by women's increased biological and social vulnerability to HIV infection, and thus social and behavioral research on microbicide acceptability has been conducted alongside, as well as separate from, the earliest product development efforts. Some acceptability and preferences issues are specific to a product's dosage form, use-requirements, and/or use indications, while others pertain to any vaginal product used for prevention of HIV or pregnancy. Although most of the work cited here was published since 2010, it draws on a much longer trajectory of research. Copyright © 2015. Published by Elsevier B.V.
    Advanced Drug Delivery Reviews 02/2015; DOI:10.1016/j.addr.2015.02.004 · 12.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Men and women engaged in unprotect receptive anal intercourse (RAI) are at higher risk of acquiring HIV from infected partners. The implementation of preventive strategies is urgent and rectal microbicides may be a useful tool in reducing the sexual transmission of HIV. However, pre-clinical and first clinical trials have been able to identify limitations of candidate products, mostly related with safety issues, which can in turn enhance viral infection. Indeed, the development of suitable formulations for the rectal delivery of promising antiretroviral drugs is not an easy task, and has been mostly based on products specifically intended for vaginal delivery, but these have been shown to provide sub-optimal outcomes when administered rectally. Research and development in the rectal microbicide field are now charting their own path and important information is now available. In particular, specific formulation requirements of rectal microbicide products that need to be met have just recently been acknowledged despite additional work being still required. Desirable rectal microbicide product features regarding characteristics such as pH, osmolality, excipients, dosage forms, volume to be administered and the need for applicator use have been studied and defined over the last years, and specific guidance is now possible. This review provides a synopsis of the field of rectal microbicides, namely past and ongoing clinical studies, and details on formulation and drug delivery issues regarding the specific development of rectal microbicide products. Also, future work, as required for the advancement of the field, is discussed.
    Journal of Controlled Release 09/2014; 194C:278-294. DOI:10.1016/j.jconrel.2014.09.013 · 7.26 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Microbicides are topical compounds that could prevent sexually transmitted infections. Several compounds have demonstrated activity both in vitro and in animal models, but none has been approved for use in humans. A review of >100 recent publications from MEDLINE (through October 2005) and abstracts presented at recent conferences was undertaken to describe the current status of microbicide research and to delineate why microbicides are not yet available. More than 15 candidate microbicides are currently being studied in clinical trials. Their mechanisms of action include disruption of the viral membrane by surfactants, maintenance of an acidic vaginal pH, binding to the viral envelope to block receptor binding, and blocking of receptors; they may also be combined with antiretroviral drugs. The development of safe and effective microbicides has been delayed by limitations in understanding the biological processes of human immunodeficiency virus (HIV) transmission, difficulties in extrapolation from animal models, lack of established correlates of protection, and the need to enroll and follow large cohorts of high-risk participants for several years in order to demonstrate efficacy. Safe and effective topical microbicides are biologically plausible. Several trials that are under way may demonstrate the ability of microbicides to protect against transmission of HIV, but multiple challenges remain.
    The Journal of Infectious Diseases 01/2006; 193(1):36-44. DOI:10.1086/499163 · 5.78 Impact Factor